Drug Trial Radar · NCT04551456
WJMSCs Anti-inflammatory Therapy in Coronary Artery Disease
Last checked: Nov 20, 2026Latest source record: Sep 16, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
300
Planned (sponsor's estimate)
Start
Nov 30, 2020
Primary completion
Dec 30, 2021
Study completion Dec 30, 2022
Sponsor
- Lead sponsor
- Navy General Hospital, BeijingAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Chinese PLA General Hospital; Peking University Third Hospital; Peking Union Medical College Hospital; Xijing Hospital
- First posted
- Sep 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
As biologic, epidemiologic, and clinical trial data have demonstrated, inflammation is a key driver of atherosclerosis. Recently, a gigantic proof-of-concept trial, CANTOS has demonstrated that inflammation of atherosclerosis can be effectively modulated by Canakinumab. However, fatal infections encountered and high cost in CANTOS. There is, therefore, a clear need for cheaper and safe alternatives. The latest cell biological studies have demonstrated that mesenchymal stem cells have a unique immunomodulatory function. MSCs contribute to a critical role in regulating the inflammatory microenvironment and interacting with immune cells and induce anti- inflammatory macrophages, inhibit foam cell formation, which could reduce atherosclerosis in pre-clinical studies. Therefore, in this randomized, controlled trial, our aim was to assess the safety and the anti-inflammatory efficacy of intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell (WJMSC) in patients with coronary artery atherosclerosis disease.
Conditions
- Coronary Artery Disease
Interventions
Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBSBiological
Randomised, Double-blind, Placebo-controlled, Intravenous Infusion HumanWharton' Jelly-derived Mesenchymal Stem Cells in Patients With Coronary Artery Disease
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary end point was checking incidence of adverse events (AEs) within 12 months,Time frame: up to 12 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.